FY2025 Earnings Estimate for MNPR Issued By Chardan Capital

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at Chardan Capital issued their FY2025 earnings estimates for Monopar Therapeutics in a note issued to investors on Tuesday, June 24th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings of ($2.02) per share for the year. Chardan Capital has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Chardan Capital also issued estimates for Monopar Therapeutics' FY2026 earnings at ($2.87) EPS.

Several other equities research analysts have also recently weighed in on the company. Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $76.00 target price on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $56.50.

Monopar Therapeutics Stock Up 4.9%

Monopar Therapeutics stock traded up $1.64 during midday trading on Friday, reaching $35.24. The company's stock had a trading volume of 45,914 shares, compared to its average volume of 360,395. The company has a market cap of $215.67 million, a P/E ratio of -10.13 and a beta of 1.00. The business has a 50-day simple moving average of $36.75 and a 200-day simple moving average of $34.90. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.27.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors have recently modified their holdings of the business. AlphaQuest LLC acquired a new stake in Monopar Therapeutics during the 1st quarter worth $44,000. JPMorgan Chase & Co. acquired a new stake in shares of Monopar Therapeutics during the fourth quarter worth about $45,000. Gerber LLC purchased a new position in shares of Monopar Therapeutics during the first quarter worth about $204,000. OMERS ADMINISTRATION Corp acquired a new position in Monopar Therapeutics in the 1st quarter valued at about $328,000. Finally, Jane Street Group LLC purchased a new stake in Monopar Therapeutics during the 1st quarter valued at approximately $377,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the sale, the insider now directly owns 822,255 shares of the company's stock, valued at approximately $28,778,925. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.50% of the stock is currently owned by company insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.